CCO:Management of Hepatitis B Infection (Updated)

liver411

Update: Management of Hepatitis B

CCO inPractice™ has been recently updated to reflect new guidance from the 2012 EASL HBV guidelines. Updates include:

Amended recommendations for liver biopsy and treatment
Updated recommendations on management of nucleos(t)ide analogue resistance
Updated recommendations on the frequency of HBV DNA testing for patients receiving entecavir or tenofovir
Stopping rules for patients receiving peginterferon alfa therapy
New recommendations for patients receiving entecavir or tenofovir who present with a partial virologic response